drug development

Causality-based new drug development: Some successful cases and a new challenge

Naoyuki Kamatani, MD, PhD

Mar 11, 12:00 - 13:00

B2 L5 R5209

artificial intelligence biomedicine drug development

Abstract The success rate of new drug development is extremely low. It is even lower when the new drug has a novel mechanism of action. From my experience, I propose that the success rate can be dramatically increased by predicting the effects of a drug in humans based on the causality-confirmed data. It is dangerous to develop new drugs based on the data in which causality is not confirmed. In biology, there are three different types of relationships in which the causality is confirmed, i.e. the relationships between parent and child, between gene and phenotype and between intervention and

Aldo Isaac Martínez Banderas

Ph.D. Student, Bioengineering

pharmaceutical innovation drug development

Aldo Isaac Martínez Banderas is a Ph.D. student in Sensing, Magnetism and Microsystems (SMM) Research group under the supervision of Professor Jurgen Kosel at King Abdullah University of Science and Technology (KAUST). Research Interests Aldo's research interests include pharmaceutical innovation and drug development. Currently, he is working in the area of nanomedicine employing magnetic nanowires for biomedical applications. Publications - AI. Martínez-Banderas, A. Aires, JE. Perez, N. Alsharif, FJ. Teran, JF. Cadenas, J. Kosel and AL. Cortajarena. Functionalized magnetic nanowires for